GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Cyclically Adjusted PB Ratio

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Cyclically Adjusted PB Ratio : 11.68 (As of Jun. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-01), Xenon Pharmaceuticals's current share price is $38.09. Xenon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.26. Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 11.68.

The historical rank and industry rank for Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

XENE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 11.96   Med: 20.06   Max: 36.85
Current: 11.96

During the past years, Xenon Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 36.85. The lowest was 11.96. And the median was 20.06.

XENE's Cyclically Adjusted PB Ratio is ranked worse than
92.05% of 654 companies
in the Biotechnology industry
Industry Median: 1.745 vs XENE: 11.96

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xenon Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $11.764. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.26 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xenon Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Xenon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 29.00 15.27

Xenon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.99 17.28 14.00 15.27 13.19

Competitive Comparison of Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Xenon Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=38.09/3.26
=11.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Xenon Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.764/126.2576*126.2576
=11.764

Current CPI (Mar. 2024) = 126.2576.

Xenon Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.996 99.473 2.533
201409 -4.971 99.394 -6.315
201412 5.132 98.367 6.587
201503 -5.522 99.789 -6.987
201506 -5.851 100.500 -7.351
201509 -5.849 100.421 -7.354
201512 4.243 99.947 5.360
201603 -6.289 101.054 -7.858
201606 -6.674 102.002 -8.261
201609 -5.789 101.765 -7.182
201612 3.564 101.449 4.436
201703 -6.481 102.634 -7.973
201706 -6.856 103.029 -8.402
201709 -7.253 103.345 -8.861
201712 1.997 103.345 2.440
201803 0.471 105.004 0.566
201806 1.632 105.557 1.952
201809 3.939 105.636 4.708
201812 3.711 105.399 4.445
201903 3.282 106.979 3.873
201906 2.912 107.690 3.414
201909 2.584 107.611 3.032
201912 2.994 107.769 3.508
202003 5.156 107.927 6.032
202006 5.188 108.401 6.043
202009 4.980 108.164 5.813
202012 4.673 108.559 5.435
202103 6.556 110.298 7.505
202106 6.062 111.720 6.851
202109 5.824 112.905 6.513
202112 10.503 113.774 11.655
202203 10.212 117.646 10.960
202206 12.625 120.806 13.195
202209 12.042 120.648 12.602
202212 11.528 120.964 12.032
202303 10.885 122.702 11.200
202306 10.146 124.203 10.314
202309 9.793 125.230 9.873
202312 12.311 125.072 12.428
202403 11.764 126.258 11.764

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xenon Pharmaceuticals  (NAS:XENE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Xenon Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Executives
Gary Patou director
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover director SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone director 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer director, officer: PRESIDENT & CEO C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney officer: Chief Medical Officer 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio officer: Chief Legal Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin officer: Chief Financial Officer 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin officer: SVP Bus. & Corp. Development C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield officer: SVP, Drug Discovery 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von officer: Chief Commercial Officer 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Headlines